Total Wealth Planning & Management Inc. Cuts Stock Position in Johnson & Johnson $JNJ

Total Wealth Planning & Management Inc. decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,972 shares of the company’s stock after selling 61 shares during the quarter. Total Wealth Planning & Management Inc.’s holdings in Johnson & Johnson were worth $759,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. GFG Capital LLC purchased a new stake in Johnson & Johnson during the 2nd quarter valued at about $35,000. Highline Wealth Partners LLC lifted its stake in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after buying an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $48,000. Finally, von Borstel & Associates Inc. purchased a new position in Johnson & Johnson in the 1st quarter worth approximately $49,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $190.66 on Friday. The company has a 50-day moving average price of $178.48 and a 200-day moving average price of $163.77. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $192.10. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $459.16 billion, a P/E ratio of 20.39, a PEG ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $24.02 billion for the quarter. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is 55.61%.

Analysts Set New Price Targets

Several analysts have commented on the company. Bank of America increased their target price on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the company an “overweight” rating in a research note on Friday, October 3rd. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Finally, Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $176.00 to $178.00 and gave the company an “equal weight” rating in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $192.94.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.